[ad_1]
Moderna’s interim analysis was based on 95 infections among trial participants who received either a placebo or a vaccine. Of these cases, only five infections were registered among those who received the vaccine, which is vaccinated with two doses, with a difference of 28 days.
Moderna’s analyzes included, on its journey to develop the vaccine, 11 severe cases of people attacked by the Corona virus, as specified in the study protocol, as the vaccine demonstrated its effectiveness.
The sample of vaccine participants also included a number of seniors over the age of 65, 20 of whom were of Hispanic, African and Asian descent, to ensure the effectiveness of the vaccine in different segments.
One of the main advantages of the Moderna vaccine is that it does not need to be stored in extremely cold temperatures like the Pfizer vaccine, which makes it easy to distribute.
Moderna expects the vaccine to be stable at normal refrigerant temperatures of 2 to 8 degrees Celsius for 30 days, and can be stored for up to six months at minus 20 degrees Celsius.
Symptoms
Regarding symptoms associated with receiving the vaccine, Moderna did not record any public safety issues, including muscle and joint pain, fatigue and fever, in a very small percentage of those who received the vaccine.
Moderna said that "This is a crucial moment in the development of our candidate vaccine against COVID-19", She added "Since the beginning of January we have been working to combat this virus with the intention of protecting as many people as possible around the world.".
Stephane Bansel, CEO of Moderna, said: "This positive interim analysis from our phase 3 study gave us our first clinical verification that our vaccine can prevent COVID-19.".
“>
Moderna, a leader in the pharmaceutical and vaccine industry, stated that its third trial of the vaccine involved 30,000 participants in the United States and was conducted in cooperation with the National Institute of Allergy and Infectious Diseases.
Moderna indicated on its website that the trial met the statistical criteria previously defined in the study protocol to measure the effectiveness of the vaccine, which reached 94.5%.
The vaccine’s efficacy judgment, which Moderna has been developing for months, is based on the analysis and adjudication of confirmed COVID-19 cases starting two weeks after receiving the second dose of the vaccine.
Moderna’s interim analysis was based on 95 infections among trial participants who received either a placebo or a vaccine. Of these cases, only five infections were registered among those who received the vaccine, which is vaccinated with two doses, with a difference of 28 days.
Moderna’s analyzes included, on its journey to develop the vaccine, 11 severe cases of people attacked by the Corona virus, as specified in the study protocol, as the vaccine demonstrated its effectiveness.
The sample of vaccine participants also included a number of people 65 and older, 20 of whom were of Hispanic, African and Asian descent, to ensure the effectiveness of the vaccine in different segments.
One of the main advantages of the Moderna vaccine is that it does not need to be stored in extremely cold temperatures like the Pfizer vaccine, which makes it easy to distribute.
Moderna expects the vaccine to be stable at normal refrigerant temperatures of 2 to 8 degrees Celsius for 30 days, and can be stored for up to six months at minus 20 degrees Celsius.
Symptoms
Regarding symptoms associated with receiving the vaccine, Moderna did not record any public safety issues, including muscle and joint pain, fatigue and fever, in a very small percentage of those who received the vaccine.
Moderna said: “This is a crucial moment in the development of our candidate vaccine to combat Covid-19” and added that “since the beginning of January, we have been working to confront this virus with the intention of protecting as many people as possible. all over the world”.
“This positive interim analysis from our Phase III study has given us the first clinical verification that our vaccine can prevent Covid-19 disease,” said Stephan Bansel, CEO of Moderna.
[ad_2]
